1 / 11

Overview of Kuros Intellectual Property

Overview of Kuros Intellectual Property. Kuros Biosurgery AG. Kuros`IP Portfolio // Fibrin Technology (FRT). Kuros licensed 10 patent families for Fibrin Technology from: Licensor No Patent Families ETH and University of Zürich 6 American Red Cross 3

aliza
Download Presentation

Overview of Kuros Intellectual Property

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Overview of Kuros Intellectual Property Kuros Biosurgery AG

  2. Kuros`IP Portfolio // Fibrin Technology (FRT) Kuros licensed 10 patent families for Fibrin Technology from: Licensor No Patent Families ETH and University of Zürich 6 American Red Cross 3 California Institute of Technology 1 - exclusively; -in almost all fields; - worldwide

  3. Kuros` IP Portfolio (I): in use Covalentlinking technology Growth Factor Small Bioactive Factor Degradation Site Degradation Site TG TG fibrin matrix fibrin matrix

  4. Kuros` IP Portfolio (I): in use Growth Factor TG Granted patents US 2 (US 6,331,422; US 6,607,740) Independent claims covering: • Composition comprising fibrin network and TG-peptide. • Method of making the fibrin network plus attached TG-peptide Pending applications US: 3 PCT (EP, JP, MX, CA): 3 (US 2003/0187232; US 2004/0082513; US 2003/0166833; WO98/43686; WO 01/83522; WO 03/052091) Claims pending covering: • A kit comprising fibrinogen, factor XIIIa, thrombin and TG-bioactive factor • A kit comprising fusion peptide with PTH and crosslinkable substrate domain • Fusion protein comprising protein or peptide and a TG-domain • Fusion protein comprising bioactive factor, a TG- domain and a degradation site • Fusion peptide comprising PTH and a crosslinkable substrate domain • Various claims on matrix and methods of forming a matrix

  5. Kuros` IP Portfolio (3): not in use Heparin Technology Concept I Concept II Growth Factor Growth Factor Heparin Heparin heparin-bdg.peptide TG TG fibrin matrix fibrin matrix

  6. Kuros` IP Portfolio (3) Growth Factor Heparin TG Heparin concept I Granted patents: US 1 (US 6,468,731) Pending applications: US 1 (not issued) possibility to file divisionals in EP, JP, MX, CA Claims cover Fibrin matrix + TG-heparin (or heparin like) linked to matrix + heparin binding growth factor Method of making a matrix for the controlled delivery of growth factors Fusion protein comprising a two domains, first is heparin or heparin- like compound, second is factor XIIIa substrate domain coupled to the first domain

  7. Growth Factor Heparin HB-peptide TG Kuros` IP Portfolio (3) Heparin concept II Granted patents: US 1 (US 6,723,344) Pending applications: US 1 (US 2001/0020086, allowed ; WO 00/64481)) Claimscover: Fusion protein comprising a growth factor domain and a heparin binding domain Method of making a matrix by adding (i) TG-heparin binding peptide (ii) heparin and (iii) a heparin binding growth factor Fibrin matrix + TG-heparin binding peptide linked to matrix+ heparin or heparin like compound + heparin binding growth factor

  8. Kuros IP Portfolio (2): in use ARC and Kuros „mixing-in“ technology Deglycosylated growth factor Small bioactive Factor Growth Factor fibrin matrix

  9. Kuros IP Portfolio (2): in use ARC number of applications - granted therefrom: (see summary) US 8 ; AU 3 (granted 1); CA 3; EP 4 (granted 2); JP 3 (granted 1) Broadest claims cover: Delivery system from a fibrin matrix with a sustained release time period greater than that achieved by simple diffusion; bioactive factor in matrix above its solubility level (various applications and patents cover a variety of biocative factors) Method for treating wounded tissue with an unsupplemented fibrin sealant powder (no fibrinolysis inhibitor) Fibrin plus DBM/BMP Fibrin sealant bandage without any supplements Fibrin sealant foam comprising fibrinogen and an agent which causes fibrinogen to foam

  10. Kuros IP Portfolio: in use // SRT Technology A + B : monomeric polyethylenglycol molecules C: network of A +B B A : bioactive factor • Granted US patent : 1 • Pending: 2 US, EP, JP, CA, MX, AU • 1. biomaterial formed by the particular kind of monomers, method of formation and use. • particular linker chemistry of bioactive factors to the biomaterial to allow sustained delivery • 3. The particular gel architecture and molecules in use C

  11. Vertebroplasty Principle: same as for SRT Technology however different monomers. Pending applications in US and PCT Claims: Use of a two-component composition for hard tissue augmentation, biomaterial, kit of parts, in-situ crosslinkable composition PCT examination report positive on the broad use claim.

More Related